Literature DB >> 27714413

[Adjuvant study of high-risk muscle invasive urothelial carcinoma : Open-label, multicenter, randomized phase III study with atezolizumab (anti-PD-L1 antibody) as adjuvant therapy compared with observation in patients with high-risk muscle invasive urothelial carcinoma after surgical resection (IMvigor010)- study AB 53/15 of the AUO].

H Rexer1, M Retz2, P Albers3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27714413     DOI： 10.1007/s00120-016-0248-5

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


× No keyword cloud information.
  1 in total

1.  Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers.

Authors:  Katrijn Broos; Marleen Keyaerts; Quentin Lecocq; Dries Renmans; Tham Nguyen; David Escors; Adrian Liston; Geert Raes; Karine Breckpot; Nick Devoogdt
Journal:  Oncotarget       Date:  2017-06-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.